NSCLC
CTD - Clinical Trials Data
Abbreviations
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–PositiveMetastatic NSCLC
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
© 2021 - 2024 | MedAgora Consulting srl